Zobrazeno 1 - 10
of 113
pro vyhledávání: '"M, Tomblyn"'
Autor:
Linda J. Burns, Claudio G. Brunstein, Mukta Arora, John H. Kersey, Bruce R. Blazar, Kathryn E. Dusenbery, Michael R. Verneris, Marcie Tomblyn, Paul J. Orchard, Margaret L. MacMillan, Dan S. Kaufman, Jeffrey S. Miller, Arne Slungaard, Philip B. McGlave, John E. Wagner, K. Scott Baker, Daniel J. Weisdorf, Todd E. DeFor, M. Tomblyn, Gregory M. Vercellotti
Publikováno v:
Journal of Clinical Oncology. 27:3634-3641
Purpose Analysis of hematopoietic cell transplantation (HCT) for high-risk or recurrent acute lymphoblastic leukemia (ALL) using different donor sources is confounded by variable conditioning and supportive care. Patients and Methods We studied 623 c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70fac9b385e39006e08e639e8dfe0231
https://doi.org/10.1200/jco.2008.20.2960
https://doi.org/10.1200/jco.2008.20.2960
Publikováno v:
Clinical Leukemia. 3:58-64
Central nervous system (CNS) relapse in patients with acute promyelocytic leukemia (APL) is an uncommon event but increasingly reported in the all-trans-retinoic acid (ATRA) era. No standard of care for treating these patients currently exists. We de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d565c333a52b2898b9003f4cde2cf324
https://doi.org/10.3816/clk.2009.n.007
https://doi.org/10.3816/clk.2009.n.007
Autor:
Hillard M. Lazarus, M. Tomblyn
Publikováno v:
Bone Marrow Transplantation. 42:569-579
Donor lymphocyte infusions (DLI) often are used after allo-SCT to augment the graft-versus-tumor effect. Timing of infusion varies according to indication, for example to treat tumor recurrence, as a planned strategy to prevent disease relapse in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::732b86f413ed4febcf9ff8a9575b258a
https://doi.org/10.1038/bmt.2008.259
https://doi.org/10.1038/bmt.2008.259
Autor:
M. Tomblyn, Jeffrey S. Miller, Tyson B. Rogers, Daniel J. Weisdorf, Bruce R. Blazar, Linda J. Burns, P B McGlave, John E. Wagner, Charlotte P. Lee
Publikováno v:
Bone Marrow Transplantation. 40:111-118
Hematopoietic growth factors alone or in combination with myelosuppressive chemotherapy are used to mobilize peripheral blood stem cells for autologous transplantation. To identify characteristics of successful mobilization with granulocyte colony-st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2a1d3293ee26d776a2a2e259b76fb44
https://doi.org/10.1038/sj.bmt.1705708
https://doi.org/10.1038/sj.bmt.1705708
Autor:
Susanta K. Hui, Patrick D. Higgins, Michael R. Verneris, Bruce J. Gerbi, C. Fraser, S. K. Baker, M. Tomblyn, Brenda J. Weigel, Kathryn E. Dusenbery
Publikováno v:
Acta Oncologica. 46:250-255
Total body irradiation (TBI) has been widely utilized as part of the conditioning regimen for hematopoietic cell transplantation [1]. However, with traditional TBI techniques the entire body is irr...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e6af5d6350d88de1c112a741178c9d2
https://doi.org/10.1080/02841860601042449
https://doi.org/10.1080/02841860601042449
Autor:
M Tomblyn, Martin S. Tallman
Publikováno v:
Seminars in Oncology. 30:502-508
In the past three decades, improvements in the treatment of acute myeloid leukemia (AML) have increased survival in patients younger than 55 years without significant survival impact in older individuals. Unfortunately, many patients, regardless of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf1bf4292c10bbb697b897e0f60692bb
https://doi.org/10.1016/s0093-7754(03)00234-3
https://doi.org/10.1016/s0093-7754(03)00234-3
Autor:
M Tomblyn, Jane N. Winter
Publikováno v:
Expert Review of Anticancer Therapy. 3:281-294
The PARMA trial clarified the role of hematopoietic stem cell transplant in patients with non-Hodgkin's lymphoma in chemotherapy-sensitive relapse. With the goal of improving overall response and survival rates, hematopoietic stem cell transplant has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf4dabb86fae989285ef937c98c216cf
https://doi.org/10.1586/14737140.3.3.281
https://doi.org/10.1586/14737140.3.3.281
Autor:
Jan Storek, Kent A. Sepkowitz, Tom Chiller, Jo Anne H. Young, Ronald E. Gress, Herman Einsele, John R. Wingard, Michael Boeckh, M. Tomblyn
Publikováno v:
Bone Marrow Transplantation. 44:453-455
Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2d4375edbb9010304b2921f5fda2adb
https://doi.org/10.1038/bmt.2009.254
https://doi.org/10.1038/bmt.2009.254
Autor:
C. Bennett, Steven Trifilio, Juan Gea-Banacloche, Paul Szabolcs, Michael Boeckh, Min Chen, M. Tomblyn, John P. Klein
Publikováno v:
Biology of Blood and Marrow Transplantation. 18(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f354605a8198bfa3bde11df1ead8d27
Publikováno v:
Bone marrow transplantation. 44(8)
With allogeneic HCT, the life of the recipient may depend on the timely selection of an acceptable HLA-matched donor. Only a limited number of HLA-matched donors might be identified. Hence, the transplant physician may have to accept a higher risk fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::778ee8d1dd8b652ca8200f936c25b4b8
https://pubmed.ncbi.nlm.nih.gov/19861979
https://pubmed.ncbi.nlm.nih.gov/19861979